Mangalam Drugs Reports Significant Financial Decline, Facing Profitability Challenges in May 2025

Mangalam Drugs and Organics, a microcap player in the Pharmaceuticals & Biotechnology sector, has reported its financial results for the quarter ending March 2025. The results, declared on May 17, 2025, indicate a notable shift in the company's financial landscape.
The Profit After Tax (PAT) for the quarter stands at Rs 0.06 crore, reflecting a significant decline compared to the average PAT of Rs 2.55 crore over the previous four quarters. This trend suggests challenges in maintaining profitability. Similarly, net sales have also shown a downward trajectory, recorded at Rs 73.04 crore, which is the lowest in the last five quarters and represents a decline from the average of Rs 86.86 crore in prior periods.

Additionally, the company has experienced the highest interest costs in the last five quarters, amounting to Rs 4.03 crore, indicating increased borrowings. This rise in interest expenses could further impact financial stability. The earnings per share (EPS) have also reached a low of Rs 0.04, signaling a reduction in earnings available to shareholders.

In light of these developments, Mangalam Drugs has undergone an adjustment in its evaluation, reflecting the current financial challenges faced by the company.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.